MMSC - ETF AI Analysis
Top Page
First Trust Multi-Manager Small Cap Opportunities ETF (MMSC)
Rating:63Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered strong gains so far this year, suggesting its strategy has worked well in the recent market environment.
High-Performing Top Holdings
Several of the largest positions, especially in health care and technology, have shown strong year-to-date performance, helping lift the fund’s overall returns.
Broad Sector Diversification Within Small Caps
The fund spreads its investments across many sectors, with meaningful exposure to health care, technology, and industrials, which helps reduce the impact if any single industry struggles.
Negative Factors
High Expense Ratio
The ETF charges relatively high annual fees, which can eat into investor returns over time compared with lower-cost small-cap funds.
Short-Term Performance Weakness
Recent one-month performance has been weak, showing that the fund can be sensitive to short-term market swings in small-cap stocks.
Heavy U.S. Concentration
With almost all assets in U.S. companies and very little international exposure, investors are highly dependent on the health of the U.S. small-cap market.
MMSC vs. SPDR S&P 500 ETF (SPY)
AUM52.97M
RegionNorth America
Expense Ratio0.95%
Beta1.22
IssuerFirst Trust
Inception DateOct 13, 2021
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,766
30 Day Avg. Volume4,606
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
36.19Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering207
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MMSC Summary
The First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) focuses on small, fast-growing U.S. companies rather than following a traditional index. It mainly invests in health care, technology, and industrial businesses, aiming to find tomorrow’s potential winners early. Examples of holdings include Crinetics Pharmaceuticals and Xometry, both smaller firms working in specialized areas. Investors might consider MMSC for growth and diversification beyond large, well-known stocks. However, because it concentrates on small growth companies, its price can be more volatile and can go up and down sharply with changes in the market.
How much will it cost me?The First Trust Multi-Manager Small Cap Opportunities ETF (Ticker: MMSC) has an expense ratio of 0.95%, meaning you’ll pay $9.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, leveraging multiple asset managers to identify growth opportunities in small-cap stocks.
What would affect this ETF?The First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) could benefit from strong growth in sectors like technology and healthcare, which make up a significant portion of its holdings, especially if innovation and demand in these areas continue to rise. However, small-cap stocks are often more sensitive to economic downturns, interest rate hikes, and market volatility, which could negatively impact the ETF's performance. Additionally, regulatory changes or challenges in the U.S., where the fund is geographically focused, could also influence its future outcomes.
MMSC Top 10 Holdings
MMSC leans heavily into U.S. small-cap health care and tech, and that’s where the story really unfolds. Crinetics Pharmaceuticals and Spyre Therapeutics have been rising, helping power the fund’s biotech tilt, while Silicon Motion adds a steady boost from the semiconductor side despite some choppy trading. On the flip side, Twist Bioscience and Xometry have been more mixed, with recent weakness acting like a small anchor on otherwise strong year-to-date runs. Overall, performance is being driven by a concentrated bet on innovative, higher-risk U.S. growth names.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Twist Bioscience | 1.57% | $830.58K | $7.25B | 351.97% | 43 Neutral | |
| Xometry | 1.44% | $762.90K | $5.34B | 110.34% | 55 Neutral | |
| Travere Therapeutics | 1.37% | $723.49K | $5.78B | 252.37% | 56 Neutral | |
| Guardant Health | 1.25% | $661.82K | $22.61B | 205.13% | 61 Neutral | |
| Crinetics Pharmaceuticals | 1.21% | $641.14K | $8.92B | 207.34% | 61 Neutral | |
| FirstCash | 1.17% | $620.76K | $8.78B | 53.07% | 74 Outperform | |
| JFrog | 1.16% | $613.70K | $10.84B | 109.08% | 73 Outperform | |
| ― | 1.14% | $604.44K | ― | ― | ― | |
| Spyre Therapeutics | 1.14% | $603.33K | $9.25B | 590.69% | 43 Neutral | |
| VSE | 1.08% | $573.65K | $6.12B | 43.99% | 67 Neutral |
MMSC Technical Analysis
Positive
―
Price Trends
28.21
Positive
27.21
Positive
25.91
Positive
Market Momentum
0.15
Negative
59.97
Neutral
95.15
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MMSC, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 27.98, equal to the 50-day MA of 28.21, and equal to the 200-day MA of 25.91, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 59.97 is Neutral, neither overbought nor oversold. The STOCH value of 95.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MMSC.
MMSC Peer Comparison
Comparison Results
Performance Comparison
MMSC
First Trust Multi-Manager Small Cap Opportunities ETF
28.99
7.13
32.62%
TMFS
Motley Fool Small-Cap Growth ETF
―
―
―
ACSG
American Century Small Cap Growth Insights ETF
―
―
―
SGRW
Harbor Active Small Cap Growth ETF
―
―
―
SAWS
AAM Sawgrass US Small Cap Quality Growth ETF
―
―
―
FSEG
Fidelity Enhanced Small Cap Growth ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents